Introduction {#sec1-1}
============

Infectious diseases are common in liver disease patients with cirrhosis and exert one of the most important reasons for morbidity and mortality in critical care units (CCUs). Pneumonia is one of the most common infections in liver disease patients with cirrhosis admitted in CCU.\[[@ref1][@ref2]\] The prevalence of pneumonia is reported in about 21.4% of cirrhotic patients with mortality rates as high as 37%--41%.\[[@ref3]\] There are several consequences of pneumonia in cirrhotic patients which include acute on chronic liver failure, multiple organ failure, sepsis, prolonged hospitalization, and mortality.\[[@ref4]\] Although pneumonia exhibits higher mortality in patients with cirrhosis, majority of the studies focused on bacterial pneumonia as the most common cause of pneumonia in cirrhotic patients; other pathogens especially are usually underestimated in such patients and are often not underreported.\[[@ref5][@ref6]\] There are very few studies which have shown the influence of respiratory viruses (RVs) in clinical outcome of cirrhotic patients in CCU.\[[@ref7][@ref8][@ref9]\] Till now, there is no published study showing the prevalence of RVs and their bacterial coinfections in cirrhotic patients admitted in CCU care. With this background, the purpose of the current study is to investigate the prevalence of RVs in cirrhotic patients with pneumonia and its impact on the clinical outcome of cirrhotic patients with pneumonia admitted in CCUs.

Material and Methods {#sec2-1}
--------------------

This is a prospective study, done over a period of 1 year from January 2016 to December 2016, in CCUs in liver center, and All consecutive cirrhotic patients who had developed clinical signs and symptoms of pneumonia were included. Pneumonia was defined as a new infiltrate focus on chest radiological examination and one or more symptoms as follows: respiratory symptoms (i.e. cough, chest pain, and dyspnea), sign of infection (fever \>38°C, and/or white blood cell count \>12,000/mm^3^ or \<4000/mm^3^.\[[@ref10]\] The exclusion criteria included: (1) under 18 years; (2) pregnancy; (3) patients with immunosuppression (including patients with chemotherapy and radiotherapy and patients with drug-induced immunosuppression as a result of cytotoxic or corticosteroids \[defined as \>1 mg/kg prednisone for \>1 month\]); (4) bone marrow or solid organ transplantation; (5) patients with hepatocellular carcinoma or with other types of carcinoma; and (6) HIV infection. Bronchoalveolar lavage (BAL) or throat swab/nasal swab (TS/NS) was collected from cirrhotic patients with pneumonia. BAL sample was collected by trained pulmonologist patients on mechanical ventilator because the TS/NS could not be from them. TS and NS were collected from nonventilated patients with pneumonia. All samples were transported in viral transport media immediately to the virology laboratory on ice. All the samples were stored at −80°C till further processing. Complete clinical characteristics of the patient and other biochemical parameters were recorded from the hospital information system. The study was approved by the ethical committee (IRB Reference No: F.25/5/81/ILBS/AC/2015/9601) of the institute.

Clinical definitions {#sec2-2}
--------------------

A patient admitted to the intensive care unit (ICU) with the diagnosis of pneumonia without prior contact of health settings was considered as having community-acquired pneumonia (CAP). Infection in a patient who developed clinical features of pneumonia after 48 h of admission was considered as hospital-acquired pneumonia (HAP). Impact of clinical outcome due to viral pneumonia was assessed if there was a requirement for either invasive mechanical ventilation, extended duration of stay in ICU (\>7 days), or mortality of patients.

### Multiplex quantitative real-time polymerase chain reaction for respiratory viruses {#sec3-1}

In all the samples, nucleic acids (DNA/RNA) were extracted using commercial kit (RTP DNA/RNA Virus Mini Kit, Stratec Molecular, Birkenfeld, Germany) according to the manufacturer\'s instructions. Multiplex quantitative real-time polymerase chain reaction was done using commercially available kit capable of detection and quantification of 33 different pathogens (21 viruses and 12 bacteria; FTD-RP33, Fast-Track Diagnostics, Luxembourg) as per the manufacturer\'s protocol \[[Table 1](#T1){ref-type="table"}\]. Results were expressed as copies/ml, and the linear range of the assay is 10^2^--10^9^ copies/ml. Data were presented as mean ± standard deviation or an absolute number and percentage. To compare categorical variables, Chi-square test was used, and for continuous variables, Student\'s *t*-test was used. *P* \< 0.05 was considered statistically significant. Data were recorded and analyzed using SPSS (version 21.0; SPSS). (IBM, Armonk, NY, United States of America).

###### 

List of respiratory pathogens identified by an available commercial kit

  Respiratory virus             Respiratory bacteria/other respiratory pathogens
  ----------------------------- --------------------------------------------------
  Influenza A                   *Staphylococcus aureus*
  Influenza B                   *Chlamydia pneumoniae*
  Influenza C                   *Haemophilus influenzae B*
  Influenza A (H1N1) pdm 09     *Streptococcus pneumoniae*
  Parainfluenza virus 1         *Klebsiella pneumoniae*
  Parainfluenza virus 2         *Legionella pneumophila*
  Parainfluenza virus 3         *Pneumocystis carinii pneumoniae\**
  Parainfluenza virus 4         *Salmonella* species
  Coronavirus NL63              *Moraxella catarrhalis*
  Coronavirus 229E              *Bordetella pertussis*
  Coronavirus OC43              *Haemophilus influenzae*
  Coronavirus HKU1              *Mycoplasma pneumoniae*
  Human metapneumovirus         
  Rhinovirus                    
  Respiratory syncytial virus   
  Adenovirus                    
  Enterovirus                   
  Parechovirus                  
  Bocavirus                     

\**Pneumocystis carinii* pneumoniae=Included in yeast-like fungal organism

Results {#sec1-2}
=======

A total of 1076 liver disease patients with cirrhosis were admitted in ICU during the study period. Diagnosis of pneumonia was made in 135 (11.2%) cirrhotic patients. Eighty-six (64.4%) patients had HAP and 49 (36.3%) patients had CAP. The baseline characteristics of the study population are depicted in [Table 2](#T2){ref-type="table"}. A total of 88 patients (65.1%) underwent bronchoscopy BAL for etiologic diagnosis of pneumonia, and TS/NSs were collected from 47 (34.9%) patients. [Figure 1](#F1){ref-type="fig"} shows the workflow and distribution of respiratory pathogens in all patients.

###### 

Baseline characteristics of the study population

  Baseline parameters                          Total number of patients (*n*=135)
  -------------------------------------------- ------------------------------------
  Mean age±SD (years)                          48.4±13.1
  Male (%)                                     112 (83.3)
  Mean leukocyte count±SD cubic/mm^3^          13.9±8.9
  Normal range cubic/mm^3^                     4-11
  Length of hospital stay, median (IQR) days   11 (2-32)
  Mean CTP score±SD                            11.75±2.0
  Mean MELD score±SD                           29±7.4
  Underlying etiology, *n* (%)                 
   Ethanol-related chronic liver disease       95 (70.3)
   Autoimmune liver disease                    15 (11.6)
   Chronic hepatitis B-related liver disease   26 (19.3)
   Chronic hepatitis C-related liver disease   9 (6.7)

SD=Standard deviation, IQR=Interquartile range, CTP=Child--Turcotte--Pugh, MELD=Model for End-Stage Liver Disease

![Work flow and algorithm in respiratory viruses testing in liver disease patients](JLP-11-356-g001){#F1}

The overall prevalence of RVs was found in 30 (22.2%) cirrhotic patients with pneumonia, and both viral and bacterial coinfections were seen in 16 (11.8%) cirrhotic patients with pneumonia. The proportion of RV infections were little higher in HAP group than in the CAP group though not significant (17 \[56.7%\] and 13 \[43.3%\], respectively, *P* = 0.47). The comparison of various parameters of cirrhotic patients with and without RV infection is shown in [Table 3](#T3){ref-type="table"}. Overall, rhinovirus (RhV) was the most common identified virus in 9 (6.0%) cirrhotic patients, followed by influenza A (Flu A) in 5 (3.7%) patients, human coronavirus (HCoV) in 3 (2.2%) patients, respiratory syncytial virus (RSV) in 3 (2.2%) patients, human parainfluenza virus (HPIV) in 2 (1.4%) patients, and human metapneumovirus and human adenovirus (HAdV) in one each of the patients. Dual viral infections such as HAdV + HPIV, HCoV + RSV, and HAdV + RhV were found in one each of the patients, respectively \[[Table 4](#T4){ref-type="table"}\]. The seasonal distribution of various RVs is described in [Figure 2](#F2){ref-type="fig"}. RhV was present throughout the year. Flu A virus and RSV were mainly present in winter months. HCoV, HAdV, and HPIV were mainly present in summer and early winter seasons. Overall, mortality was seen in 50 (37.0%) cirrhotic patients with pneumonia in ICU. Mortality in cirrhotic patients with RV infection was higher than patients with viral--bacterial coinfection (25 \[83.3%\] and 7 \[43.3%\], respectively), but the difference was not significant (*P* = 0.12). The difference of mortality of patients with RV infection versus patients without RV infection was significant (25 \[83.3%\] and 11 \[12.3%\], P \< 0.001, respectively). The patients with the median ICU stay of cirrhotic patients with pneumonia were 11 days (interquartile range \[IQR\]: 2--23 days). There was no significant difference in median length of stay of patients in viral infections and viral--bacterial coinfection (9.0 \[IQR: 2--30\] and 10 \[IQR: 5--32\] days, respectively). The patients without viral infections had a shorter duration of stay CCUs, 5.0 (IQR:2--23) da.

###### 

Comparison of various parameters of cirrhotic patients with and without respiratory viruses infection

  Parameters                           Patients with RV infection (*n*=30), *n* (%)   Patients without RV infection (*n*=89), *n* (%)   OR (95% CI)              *P*
  ------------------------------------ ---------------------------------------------- ------------------------------------------------- ------------------------ ---------
  Age\>65 years                        4 (13.3)                                       12 (11.4)                                         0.875 (0.2576-2.8519)    0.8016
  Male gender                          27 (90)                                        85 (95.5)                                         0.8995 (0.4969-1.6282)   0.7264
  CAP                                  13 (43.3)                                      25 (28.08)                                        0.549 (0.25-1.20)        0.1341
  HAP                                  17 (56.6)                                      60 (67.4)                                         1.0084 (0.5138-1.9791)   0.9806
  BAL sample                           22 (73.3)                                      68 (76.4)                                         0.88 (0.47-1.65)         0.69
  Mechanical ventilation requirement   22 (73.3)                                      68 (76.4)                                         0.88 (0.47-1.65)         0.69
  Mortality                            25 (83.3)                                      11 (12.35)                                        0.12 (0.05-0.28)         \<0.001

RVs=Respiratory viruses, OR=Odds ratio, CI=Confidence interval, CAP=Community-acquired pneumonia, HAP=Hospital-acquired pneumonia, BAL=Bronchoalveolar lavage

###### 

Distribution of respiratory pathogens and their mode of acquisition in patients

  Identified pathogens                        Total (*n*=135)   CAP (*n*=49)   HAP (*n*=86)   *P*
  ------------------------------------------- ----------------- -------------- -------------- -------
  Isolated viral etiology                     30                13             17             0.47
  RhV                                         9                 3              6              0.85
  Flu A                                       5                 4              1              0.85
  HCOV                                        3                 0              3              0.19
  RSV                                         3                 0              3              0.19
  HPIV                                        2                 1              1              0.69
  HAdV + RhV                                  2                 1              1              0.69
  HMPV                                        1                 1              0              0.18
  HAdV                                        1                 1              0              0.18
  HAdV + HPIV                                 1                 0              1              0.45
  HCOV + RSV                                  1                 0              1              0.45
  HPIV + HAdV                                 1                 1              0              0.18
  Flu A H1N1 (pdm 09)                         1                 1              0              0.45
  Isolated-bacterial etiology                 54                22             32             0.57
  *Klebsiella pneumoniae*                     39                4              35             0.009
  *Staphylococcus aureus*                     12                1              11             0.05
  *Streptococcus pneumoniae*                  1                 1              0              0.45
  *Legionella pneumophila*                    1                 1              0              0.45
  *Moraxella catarrhalis*                     1                 0              1              0.45
  Combined bacterial and viral coinfections   16                5              11             0.69

CAP=Community-acquired pneumonia, HAP=Hospital-acquired pneumonia, RhV=Rhinovirus, Flu A=Influenza A, HCOV=Human Corona virus, RSV=Respiratory syncytial virus, HPIV=Human parainfluenza virus, HAdV=Human adenovirus, PCP=*Pneumocystis carinii* pneumoniae, HMPV=Human metapneumovirus
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Discussion {#sec1-3}
==========

To the best of our knowledge, this is the first prospective study representing the investigation of viral pneumonia in cirrhotic patients in CCUs. In the present study, we evaluated the epidemiology, clinical characteristics, and prognosis of cirrhotic patients with viral pneumonia in CCUs. Specimens obtained from the upper airway as TS/NS are often used for RV testing in pneumonia patients due to ease of specimen collection in comparison to bronchoscopy collected BAL sample.\[[@ref11]\] However, in the current study, the proportion of RVs detected from BAL samples were more than TS/NS though not significant. Therefore, here comes the importance to perform bronchoscopy and collection of BAL sample in the most affected lung segment according to the radiographic signs to recover the responsible respiratory pathogen in patients with pneumonia, especially in patients having chronic liver disease. Over the past decade, several studies have consistently demonstrated RVs to be the second most common etiological factor of CAP, accounting for 13%--50% of diagnosed cases of pneumonia in noncirrhotic patients in CCUs.\[[@ref2]\] Our study has demonstrated that the proportion of RV infections was little higher in the HCAP group than in the CAP group in cirrhotic patients, which is similar to one recent study done in nonliver adult patients.\[[@ref12][@ref13]\] A high index of suspicion of viral pneumonia is always necessary in patients with cirrhosis because there are no distinctive clinical features to differentiate between viral and bacterial pneumonia.; hence, a high index of suspicion is necessary for this infection. None of the previously done studies have shown the spectrum of different RVs in liver disease patients. Only a few studies done in our center have shown the prevalence of influenza virus and its impact on the clinical outcome of cirrhotic patients.\[[@ref7][@ref8][@ref14]\] The current study has found that respiratory viral infections other than influenza virus infection are also an important etiology of pneumonia in liver disease patients with cirrhosis admitted in CCUs. Transmission dynamics and seasonal distribution of RVs are key importance in understanding and limiting burden of morbidity and mortality of pneumonia patients in CCUs.\[[@ref15]\] In the current study, no clear seasonality is seen for human RhV. Flu A virus and RSV were mainly present in winter months. This finding can inform the timing of Flu A and RSV vaccination and the judicious use of antibiotics in cirrhotic patients admitted in CCUs. Mixed viral and bacterial infections are widely described in pneumonia patients in CCUs; however, the presence of these coinfections on the cirrhotic patients' clinical outcome remains poorly studied.\[[@ref16]\] Various studies suggest that viral and bacterial coinfections lead to a higher severity ongoing disease, especially in patients with chronic disease.\[[@ref16][@ref17]\] We did not find any significant correlation in mortality and median length of stay in CCUs in patients with only RV infection and viral--bacterial confection which is not in concordance of previous done studies.\[[@ref18]\]

Our study had some limitations. First of all, our study was a single-center cohort and done in a small duration period. Considering small number of patients, our observations should be confirmed in larger sample size with more detailed subgroup in future study. Second, our study excluded cirrhotic patients with cancer and immunosuppression. Therefore, exclusions may result in statistic bias and inexact conclusion. Nevertheless, our investigation provided the first comprehensive study of the prevalence of RVs and its epidemiology in cirrhotic patients with pneumonia in CCUs. With the high morbidity and mortality rates associated with RV infections and the lack of directed antiviral therapy for most of these infections, prevention remains the mainstay for reducing their incidence and controlling transmission of RVs, especially in CCUs settings.

Conclusion {#sec1-4}
==========

RVs may contribute to significant cause of pneumonia in cirrhotic patients. Therefore, there should be a high index of suspicion, and early diagnosis by rapid molecular test for RVs should be instituted in cirrhotic patients with pneumonia in CCUs.
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